Johnson Nancy JoAnn sold $1.4M of BLLN

Johnson Nancy JoAnn (See Remarks) sold 14,000 shares of BillionToOne, Inc. (BLLN) at an average of $100.18 ($99.09–$102.34, $1.40M total) across 7 trades over 2026-06-08 to 2026-06-09 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Johnson Nancy JoAnn
Published Jun 11, 2026, 12:36 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 11, 2026, 1:00 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BLLN
Neutral
medium confidence
Mentioned
$BLLN
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BLLNNeutralLow
01

Why it matters

The disclosure provides a concrete datapoint on insider selling size, timing, and whether it was pre-arranged; it does not include operational or financial performance updates.

02

Market read

A $1.40M officer sale is a modest sentiment input, but the 10b5-1 structure limits interpretive value versus discretionary selling.

03

What to watch

Traders may overreact to insider sales; the key is whether there are concurrent news catalysts (earnings, trial updates, financing) not present in this filing.

Relevance 5/10Novelty 6/10Timing: Filed 2026-06-10; transaction dates 2026-06-08 to 2026-06-09

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for BillionToOne, Inc.

Company-level read

Ticker impact

$BLLNNeutralMedium confidence
Context

Officer Nancy JoAnn Johnson sold $1.40M of BillionToOne shares via an open-market sale under a pre-arranged 10b5-1 plan.

Expected impact

Near-term price reaction, if any, is likely limited; watch for follow-through in volume rather than a directional catalyst.

Evidence & confidence

The filing is a routine insider transaction and explicitly states a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

No sector-level implications; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Because the sale is under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish fundamentals.

Key entities

  • BillionToOne, Inc.

    Company whose officer executed open-market sales disclosed on Form 4.

  • Nancy JoAnn Johnson

    Officer who sold 14,000 shares (weighted avg ~$100.18) under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

Why is BillionToOne stock sliding today?

BillionToOne stock fell 6.2% in pre-market trading after Fuzzy Panda Research disclosed a short position and alleged regulatory and billing misconduct, including overbilling and potential unlawful practices. The company's stock had already declined from its 52-week high of $150.44, and broader market pressures contributed to the decline.

$BLLNMed

BillionToOne shares slide in pre-market trading following short-seller report

BillionToOne (BLLN) shares fell 6% premarket after a short-seller report alleged improper billing, undisclosed regulatory scrutiny, and clinical claim weaknesses. Fuzzy Panda Research, which holds a short position, cited FOIA records, anonymous sources, and billing data. The report claims potential EBITDA reduction of 80% and False Claims Act penalties up to $1.2B. BillionToOne has not responded.

$BLLNMed

BillionToOne: Q3 Earnings Snapshot

BillionToOne (BLLN) reported Q3 earnings of $17.4M, or 32 cents per share, beating estimates of 16 cents. Revenue was $123M, exceeding forecasts of $116.2M. The company expects full-year revenue between $460M and $470M. Shares have risen 39% YTD.